MX2022005811A - Sal novedosa de compuesto de terfenilo. - Google Patents
Sal novedosa de compuesto de terfenilo.Info
- Publication number
- MX2022005811A MX2022005811A MX2022005811A MX2022005811A MX2022005811A MX 2022005811 A MX2022005811 A MX 2022005811A MX 2022005811 A MX2022005811 A MX 2022005811A MX 2022005811 A MX2022005811 A MX 2022005811A MX 2022005811 A MX2022005811 A MX 2022005811A
- Authority
- MX
- Mexico
- Prior art keywords
- novel salt
- fluoro
- phenyl
- terphenyl compound
- aminopyrrolidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934923P | 2019-11-13 | 2019-11-13 | |
| PCT/JP2020/042383 WO2021095835A1 (en) | 2019-11-13 | 2020-11-13 | Novel salt of terphenyl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005811A true MX2022005811A (es) | 2022-06-08 |
Family
ID=75912767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005811A MX2022005811A (es) | 2019-11-13 | 2020-11-13 | Sal novedosa de compuesto de terfenilo. |
| MX2022005812A MX2022005812A (es) | 2019-11-13 | 2020-11-13 | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005812A MX2022005812A (es) | 2019-11-13 | 2020-11-13 | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12419858B2 (https=) |
| EP (2) | EP4058151B1 (https=) |
| JP (2) | JP7492002B2 (https=) |
| KR (2) | KR102825246B1 (https=) |
| CN (2) | CN114828844A (https=) |
| AU (2) | AU2020382379B2 (https=) |
| BR (2) | BR112022009221A2 (https=) |
| CA (2) | CA3157404A1 (https=) |
| DK (1) | DK4058151T3 (https=) |
| ES (1) | ES3034158T3 (https=) |
| FI (1) | FI4058151T3 (https=) |
| HU (1) | HUE072206T2 (https=) |
| MX (2) | MX2022005811A (https=) |
| PH (2) | PH12022551169A1 (https=) |
| PL (1) | PL4058151T3 (https=) |
| PT (1) | PT4058151T (https=) |
| TW (2) | TWI874489B (https=) |
| WO (2) | WO2021095835A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2021095835A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4337638A1 (en) * | 2021-05-11 | 2024-03-20 | Astex Pharmaceuticals, Inc. | Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile |
| US20250049757A1 (en) * | 2021-09-30 | 2025-02-13 | Taiho Pharmaceutical Co. Ltd. | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator |
| JP7788550B2 (ja) * | 2021-10-26 | 2025-12-18 | 大鵬薬品工業株式会社 | ターフェニル化合物の安息香酸塩の製造方法 |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2024229073A1 (en) * | 2023-05-02 | 2024-11-07 | Otsuka Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801518D0 (sv) * | 1988-04-22 | 1988-04-22 | Astra Pharma Prod | A novel process |
| US6225049B1 (en) | 1992-06-17 | 2001-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Human insulinoma-associated cDNA |
| CA2469649C (en) | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| EP2350317A4 (en) | 2008-10-20 | 2012-06-27 | Univ Colorado Regents | BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS |
| US8367679B2 (en) | 2008-12-09 | 2013-02-05 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| EP2419177A1 (en) | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| BR112012027062B8 (pt) | 2010-04-20 | 2021-05-25 | Fond Ieo | composto, processo para a preparação de um composto e usos do mesmo |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| WO2012157647A1 (ja) | 2011-05-16 | 2012-11-22 | 大鵬薬品工業株式会社 | 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法 |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CN104411316B (zh) * | 2012-05-09 | 2018-05-01 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| US9834521B2 (en) | 2013-03-15 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Choline kinase inhibitors |
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| US9266907B2 (en) | 2013-09-05 | 2016-02-23 | King Abdullah University Of Science And Technology | Tunable rare-earth fcu-metal-organic frameworks |
| CA3161836A1 (en) | 2013-12-11 | 2015-06-18 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| CN106061969B (zh) | 2014-01-06 | 2019-10-29 | 阿尔戈么迪克斯有限公司 | Trpa1调节剂 |
| KR102400920B1 (ko) | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| EP3285809B1 (en) | 2015-04-20 | 2019-09-11 | eFFECTOR Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EP3381896B1 (en) * | 2015-11-27 | 2023-01-18 | Taiho Pharmaceutical Co., Ltd. | Biphenyl compound or salt thereof |
| WO2018136961A1 (en) | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY |
| TWI770925B (zh) * | 2017-05-26 | 2022-07-11 | 日商大鵬藥品工業股份有限公司 | 使用有新穎聯苯化合物之抗腫瘤效果增強劑 |
| KR102361918B1 (ko) | 2017-05-26 | 2022-02-14 | 다이호야쿠힌고교 가부시키가이샤 | 신규 비페닐 화합물 또는 그의 염 |
| AU2018276611B2 (en) * | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| KR20200020899A (ko) | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법 |
| WO2019075327A1 (en) | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| AU2018377852B2 (en) | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| KR20200105662A (ko) | 2018-01-02 | 2020-09-08 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체 |
| IL289453B2 (en) | 2019-07-17 | 2026-03-01 | Summit Oxford Ltd | Process for preparing ridinilazole and its crystalline forms |
| WO2021095835A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| EP4114398A1 (en) | 2020-03-06 | 2023-01-11 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
-
2020
- 2020-11-13 WO PCT/JP2020/042383 patent/WO2021095835A1/en not_active Ceased
- 2020-11-13 PT PT208862615T patent/PT4058151T/pt unknown
- 2020-11-13 ES ES20886261T patent/ES3034158T3/es active Active
- 2020-11-13 BR BR112022009221A patent/BR112022009221A2/pt unknown
- 2020-11-13 TW TW109139799A patent/TWI874489B/zh active
- 2020-11-13 HU HUE20886261A patent/HUE072206T2/hu unknown
- 2020-11-13 DK DK20886261.5T patent/DK4058151T3/da active
- 2020-11-13 KR KR1020227019781A patent/KR102825246B1/ko active Active
- 2020-11-13 TW TW109139813A patent/TWI874490B/zh active
- 2020-11-13 PL PL20886261.5T patent/PL4058151T3/pl unknown
- 2020-11-13 EP EP20886261.5A patent/EP4058151B1/en active Active
- 2020-11-13 JP JP2022527859A patent/JP7492002B2/ja active Active
- 2020-11-13 JP JP2022519478A patent/JP7379680B2/ja active Active
- 2020-11-13 PH PH1/2022/551169A patent/PH12022551169A1/en unknown
- 2020-11-13 WO PCT/JP2020/042410 patent/WO2021095840A1/en not_active Ceased
- 2020-11-13 MX MX2022005811A patent/MX2022005811A/es unknown
- 2020-11-13 AU AU2020382379A patent/AU2020382379B2/en active Active
- 2020-11-13 PH PH1/2022/551137A patent/PH12022551137A1/en unknown
- 2020-11-13 EP EP20886658.2A patent/EP4058018A4/en active Pending
- 2020-11-13 CA CA3157404A patent/CA3157404A1/en active Pending
- 2020-11-13 AU AU2020382214A patent/AU2020382214B2/en active Active
- 2020-11-13 BR BR112022008020A patent/BR112022008020A2/pt unknown
- 2020-11-13 CA CA3158442A patent/CA3158442A1/en active Pending
- 2020-11-13 US US17/775,795 patent/US12419858B2/en active Active
- 2020-11-13 CN CN202080079021.0A patent/CN114828844A/zh active Pending
- 2020-11-13 KR KR1020227019783A patent/KR20220113390A/ko not_active Ceased
- 2020-11-13 US US17/775,800 patent/US20220387384A1/en active Pending
- 2020-11-13 CN CN202080078991.9A patent/CN114728899B/zh active Active
- 2020-11-13 FI FIEP20886261.5T patent/FI4058151T3/fi active
- 2020-11-13 MX MX2022005812A patent/MX2022005812A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005811A (es) | Sal novedosa de compuesto de terfenilo. | |
| PH12017500361A1 (en) | Novel compounds | |
| BR112017006253A2 (pt) | novos compostos | |
| MX362339B (es) | Forma de sal de un inhibidor de histona metiltransferasa humana ezh2. | |
| AR114886A1 (es) | Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético | |
| MX2022010040A (es) | Compuestos moduladores de gcn2. | |
| CL2024000758A1 (es) | Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético | |
| RU2013116924A (ru) | N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| PH12016500886A1 (en) | Treatment of homozygous familial hypercholesterolemia | |
| PY1981130A (es) | Herbicidas de piridazinona e intermedios de piridazinona utilizados para preparar un herbicida | |
| CO6710915A2 (es) | Composiciones farmacéuticas que contienen un inhibidor de dgat1 ácido 4-(4-(5-6(- trifluorometil-piridin -3- ilamino)-piridin- 2-il)fenil)cicloheiyl)-acético o sales del mismo | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| ZA202101487B (en) | Novel compounds | |
| BR112022002674A2 (pt) | Derivado de 2-aminoquinazolinona | |
| CL2023000313A1 (es) | Forma sólida de un compuesto | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| AR109950A1 (es) | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA | |
| CO6190608A2 (es) | Sal de potasio cristalina de analogos de lipoxina a4 | |
| PE20211088A1 (es) | Compuestos de isoxazolina para controlar plagas de invertebrados | |
| EA202190989A1 (ru) | Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений | |
| BR112020024299B8 (pt) | Sal de esteramina, processo para a preparação de um sal de esteramina, uso do sal de esteramina, e, composição para cuidados pessoais. | |
| ZA202213318B (en) | Antifungal agent for use in humans | |
| MX2022005864A (es) | Formas cristalinas de un inhibidor de magl. | |
| CU20220046A7 (es) | Sal de potasio del acido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1- il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético y métodos para su preparación |